COMPANY

CytoDyn

HQ: Vancouver, WA source · cytodyn.com ↗ · West Coast

Profile checked Oct 10, 2026

Keywords: HIV HIV-1-infection Coronavirus Disease 2019 HIV Infections Human Immunodeficiency Virus Metastatic Colorectal Cancer TNBC TNBC - Triple-Negative Breast Cancer Triple Negative Breast Neoplasms Metastatic Triple-Negative Breast Carcinoma Graft Vs Host Disease Nonalcoholic Steatohepatitis CCR5 Microsatellite Stable Metastatic Colorectal Cancer PRO 140 Leronlimab leronlimab (PRO 140) PRO 140 350 PRO 140 525 PRO 140 700 PRO 140 (humanized monoclonal antibody to CCR5)

24Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $18.6M (Form D filed May 11, 2026). SEC Form D 0001175680-26-000003 (May 11, 2026)
Evidence (1 event)
- May 11, 2026 · SEC Form D 0001175680-26-000003
  Name of Issuer: CytoDyn Inc.; CIK: 1175680; Address: Vancouver, WA; Submission type: D; Filing date: 2026-05-11; Industry Group: Pharmaceuticals; Date of First Sale: 2026-01-30; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 18600392; Total Amount Sold: 18600392; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Raises and deals from press releases

Raise Undisclosed round · $16.5M · announced Sep 1, 2026 Company release ↗
Source quote
- Sep 1, 2026 · Company release ↗
  “CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab :: CytoDyn Inc. (CYDY)”
Raise Undisclosed round · $17.5M · announced Mar 5, 2026 Company release ↗
Source quote
- Mar 5, 2026 · Company release ↗
  “CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab :: CytoDyn Inc. (CYDY)”

Raises announced in these releases: $34M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Sep 1, 2026 Raise Undisclosed round · $16.5M source ↗
Mar 5, 2026 Raise Undisclosed round · $17.5M source ↗
Jun 16, 2025 Trial start Phase 2: CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen source ↗
Sep 20, 2022 Trial start Phase 2: Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer source ↗
Mar 1, 2021 Trial start Phase 2: Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19 source ↗
Dec 1, 2020 Trial start Phase 2: Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis source ↗
May 1, 2020 Trial start Phase 2: Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors source ↗
Apr 16, 2020 Trial start Phase 2: Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19 source ↗
Apr 1, 2020 Trial start Phase 2: Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 source ↗
Apr 22, 2019 Trial start Phase 1/Phase 2: Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC source ↗
Jun 25, 2018 Trial start Phase 2/Phase 3: PRO 140 in Treatment-Experienced HIV-1 Subjects source ↗
Aug 29, 2017 Trial start Phase 2/Phase 3: An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study source ↗
May 14, 2017 Trial start Phase 2: A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation source ↗
Dec 7, 2016 Trial start Phase 2/Phase 3: Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection source ↗
Nov 3, 2016 Trial start Phase 2/Phase 3: An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study source ↗
Nov 18, 2014 Trial start Phase 2: An Extension of Protocol PRO 140_CD01 Study source ↗
Apr 16, 2014 Trial start Phase 2: Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection source ↗
Apr 16, 2004 Trial start Phase 1: Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers source ↗
2015-10 Trial start Phase 2/Phase 3: Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140 source ↗
2013-12 Trial start Phase 2: A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Use source ↗
2010-01 Trial start —: Observational Study of Blood Treated With Cytolin source ↗
2008-03 Trial start Phase 2: Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection source ↗
2007-12 Trial start Phase 2: PRO 140 by IV Administration in Adults With HIV-1 Infection source ↗

Upcoming milestones

2028-01 (ESTIMATED) · Phase 2 · CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen · NCT06699836

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 24

Record	Title	Phase	Status	Start	Primary completion
NCT06699836	CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen	Phase 2	Active, not recruiting	Jun 16, 2025	2028-01 (estimated)
NCT07536815	An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)	Not listed	Available	Not listed	Not listed
NCT02859961	Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection	Phase 2/Phase 3	Completed	Dec 7, 2016	Sep 16, 2020 (actual)
NCT04504942	Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors	Phase 2	Completed	May 1, 2020	Nov 7, 2021 (actual)
NCT02990858	An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study	Phase 2/Phase 3	Terminated	Nov 3, 2016	2022-06 (actual)
NCT05271370	An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study	Phase 2/Phase 3	Terminated	Aug 29, 2017	Jun 20, 2022 (actual)
NCT04347239	Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19	Phase 2	Completed	Apr 16, 2020	Oct 24, 2021 (actual)
NCT02355184	An Extension of Protocol PRO 140_CD01 Study	Phase 2	Terminated	Nov 18, 2014	2022-06 (actual)
NCT03902522	PRO 140 in Treatment-Experienced HIV-1 Subjects	Phase 2/Phase 3	Completed	Jun 25, 2018	May 18, 2020 (actual)
NCT03838367	Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC	Phase 1/Phase 2	Terminated	Apr 22, 2019	Jul 15, 2022 (actual)
NCT04313075	A Compassionate Use Study of Leronlimab in Breast Cancer	Not listed	No longer available	Not listed	Not listed
NCT04678830	Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19	Phase 2	Completed	Mar 1, 2021	Jun 5, 2021 (actual)
NCT02737306	A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation	Phase 2	Terminated	May 14, 2017	Apr 14, 2021 (actual)
NCT02175680	Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection	Phase 2	Completed	Apr 16, 2014	Feb 2, 2015 (actual)
NCT00110591	Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers	Phase 1	Completed	Apr 16, 2004	Nov 7, 2005 (actual)
NCT04521114	Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis	Phase 2	Completed	Dec 1, 2020	Dec 29, 2021 (actual)
NCT05730673	Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer	Phase 2	Withdrawn	Sep 20, 2022	May 27, 2023 (estimated)
NCT04343651	Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19	Phase 2	Completed	Apr 1, 2020	Jul 21, 2020 (actual)
NCT02483078	Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140	Phase 2/Phase 3	Completed	2015-10	2018-02 (actual)
NCT02759042	An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study	Not listed	No longer available	Not listed	Not listed
NCT01272258	A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence	Phase 2	Withdrawn	2013-12	2017-01 (estimated)
NCT00613379	PRO 140 by IV Administration in Adults With HIV-1 Infection	Phase 2	Completed	2007-12	2008-08 (actual)
NCT00642707	Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection	Phase 2	Completed	2008-03	2008-11 (actual)
NCT01048372	Observational Study of Blood Treated With Cytolin	Not listed	Completed	2010-01	2011-01 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2026-05-11 Raise Private raise (SEC Form D): $18.6M sold; issuer “CytoDyn Inc.”. Verified from the SEC filing. SEC filing ↗